Liver cancer drug trial halted early – but holds promise for High-Risk patients
Disease control
Terminated
This study looked at whether the drug cadonilimab could help keep liver cancer from returning after surgery in patients at high risk of recurrence. It involved 45 adults who had their liver cancer completely removed. The trial was stopped early, but the goal was to see if the dru…
Phase: PHASE2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC